Stockscreener 앱 받기
0.903
0.30%
0.0027
시간 외 거래:
.91
0.007
+0.78%
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan
Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan
Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart
Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Quince Therapeutics, Inc. announced that it has received $115.000298 million in funding from a group of investors - marketscreener.com
[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
QNCX Q1 2026 Earnings: Unexpected Profit Driven by One-Time Items; Shares DipSurprise Factor Analysis - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Operating Items, Stock DeclinesNet Profit Margin - newsline.com
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
Quince Therapeutics stock (US74833Q1004): Nasdaq-listed biotech rebounds after regaining compliance - AD HOC NEWS
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics (QNCX) Edges Higher: Navigating Key Levels Near ResistanceCovered Call ETF - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by Over 200% - thelegaladvocate.com
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights
Quince Therapeutics regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com
Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
Time is ripe for Quince with Orphai buy and $187m financing - The Pharma Letter
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus
Quince Therapeutics (QNCX) Reveals Positive Phase 2a Results for LAM-001 - GuruFocus
Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics IncM&A CallSlideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha
LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan
Quince reports phase 2a data for LAM-001 in lung disease By Investing.com - Investing.com Australia
QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade
Quince acquires Orphai, raises $115M in private placement - Investing.com UK
Quince reports phase 2a data for LAM-001 in lung disease - Investing.com UK
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD By Investing.com - Investing.com South Africa
Quince acquires Orphai, raises $115M in private placement By Investing.com - Investing.com South Africa
Quince Therapeutics announces LAM-001 data - TipRanks
Quince Therapeutics Closes Orphai Deal and Secures Funding - TipRanks
QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView
UPDATEQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince announces acquisition of Orphai and up to $187 million private placement to advance pulmonary pipeline - marketscreener.com
Quince Therapeutics Acquires Orphai and Secures $187M Financing to Advance Pulmonary Rapamycin Pipeline - Minichart
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD - Investing.com Canada
Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing - TechStock²
Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan
Press Release: Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - Moomoo
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - marketscreener.com
QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com
Quince Therapeutics, Inc. acquired OrphAI Therapeutics Inc for $80.9 million. - marketscreener.com
Quince Therapeutics, Inc. announced that it expects to receive $115.000298 million in funding - marketscreener.com
QNCX Should I Buy - Intellectia AI
2.60%
0.94%
자본화:
|
볼륨(24시간):